Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Int J Oncol ; 50(2): 432-440, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28101578

ABSTRACT

Breast cancer ranks first in incidence and mortality in working age women. Cancer initiation and progression relies on accumulation of genetic and epigenetic aberrations that alter cellular processes, among them, epithelial to mesenchymal transition (EMT) denotes particularly aggressive neoplasias given its capacity to invade and metastasize. Several microRNAs (miRNA) have been found able to regulate gene expression at the core of EMT. In this study, the Affymetrix CytoScan HD array was used to analyze three different primary tumor cell isolates from Mexican breast cancer patients. We found an amplification in band 22q11.2 shared by the three samples, in the region that encodes miRNA-650. Overexpression of this miRNA has been associated with downregulation of tumor suppressors ING4 and NDRG2, which have been implicated in cancer progression. Using the Pathway Linker platform the ING4 and NDRG2 interaction networks showed a significant association with signaling pathways commonly deregulated in cancer. Also, several studies support their participation in the EMT. Supporting the latter, we found that the three primary isolates were E-cadherin negative, vimentin positive, presented a cancer stem cell-like phenotype CD44+CD24-/low and were invasive in Transwell invasion assays. This evidence suggests that the gain of region 22q11.2 contributes to trigger EMT. This is the first evidence linking miR-650 and breast cancer.


Subject(s)
Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Epithelial-Mesenchymal Transition/genetics , Gene Expression Regulation, Neoplastic/genetics , MicroRNAs/genetics , Adult , Biomarkers, Tumor/analysis , Breast Neoplasms/genetics , Carcinoma, Ductal, Breast/genetics , Cell Cycle Proteins/biosynthesis , Cell Cycle Proteins/genetics , Cells, Cultured , Chromosomes, Human, Pair 22 , Female , Flow Cytometry , Fluorescent Antibody Technique , Gene Amplification , Homeodomain Proteins/biosynthesis , Homeodomain Proteins/genetics , Humans , Mexico , Middle Aged , Oligonucleotide Array Sequence Analysis , Tumor Suppressor Proteins/biosynthesis , Tumor Suppressor Proteins/genetics
2.
Br J Cancer ; 112(12): 1866-73, 2015 Jun 09.
Article in English | MEDLINE | ID: mdl-25996206

ABSTRACT

BACKGROUND: Chronic tissue damage induced by Helicobacter pylori (HP)-driven inflammation is considered the main risk of gastric carcinoma (GC). Epstein­Barr virus (EBV) infection has also been associated with GC. In this study, we aim to address the role of EBV in inflammatory GC precursor lesions and its added risk to HP infection. METHODS: Antibodies against EBV, HP and the bacterial virulence factor CagA were measured in sera from 525 Mexican and Paraguayan patients with gastric disease. Gastric samples were characterised according to the updated Sydney classification and associations were estimated between antibody responses and severity of both tissue damage and inflammation. RESULTS: We found significant associations (odd ratios and trends) between EBV and HP copositivity and premalignant lesions and intestinal-type GC. The EBV and HP coinfection was also significantly associated with increased infiltration of immune cells. No association was found between EBV and the less inflammation-driven diffuse-type GC. CONCLUSIONS: Our study suggests that EBV co-participates with HP to induce severe inflammation, increasing the risk of progression to intestinal-type GC.


Subject(s)
Epstein-Barr Virus Infections/pathology , Helicobacter Infections/pathology , Helicobacter pylori/isolation & purification , Herpesvirus 4, Human/isolation & purification , Stomach Diseases/blood , Stomach Diseases/microbiology , Adult , Case-Control Studies , Epstein-Barr Virus Infections/blood , Epstein-Barr Virus Infections/microbiology , Epstein-Barr Virus Infections/virology , Female , Gastritis/blood , Gastritis/microbiology , Gastritis/pathology , Helicobacter Infections/blood , Helicobacter Infections/microbiology , Helicobacter Infections/virology , Humans , Latin America , Male , Mexico , Middle Aged , Paraguay , Stomach Diseases/pathology , Stomach Diseases/virology , Stomach Neoplasms/blood , Stomach Neoplasms/microbiology , Stomach Neoplasms/pathology
3.
Anticancer Agents Med Chem ; 15(7): 837-55, 2015.
Article in English | MEDLINE | ID: mdl-25783962

ABSTRACT

In solid tumors, neoplastic cells are surrounded by a specific microenvironment that integrates the extracellular matrix, lymphatic and blood vessels, and mesenchymal and immune cells, which together are known as the tumor microenvironment (TME). The TME governs many of the aggressive features of tumors, such as local invasion and metastasis. Additionally, new evidence indicates that the TME can trigger stem cell-like programs in cancer cells, forming cancer stem cells (CSC). Experimental and clinical studies suggest that CSCs are resistant to current common cancer therapies and are responsible for tumor recurrence. In this review, we will describe the TME by focusing on how matrix metalloproteinases (MMPs) and cyclooxygenase-2 (COX-2) induce stemness and sustain stem cell maintenance. This reprogramming toward a CSC phenotype may be critical in tumor cell responses to chemotherapy and relapse with more aggressive tumor clones. Therefore, therapeutic agents targeting MMPs and COX-2 in the tumor microenvironment may become important drugs to control the establishment of CSCs and in the overall prognosis of the disease.


Subject(s)
Cyclooxygenase 2/metabolism , Matrix Metalloproteinases/metabolism , Neoplasms/enzymology , Neoplastic Stem Cells/enzymology , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Cellular Reprogramming , Cyclooxygenase 2 Inhibitors/pharmacology , Cyclooxygenase 2 Inhibitors/therapeutic use , Drug Resistance, Neoplasm , Epithelial-Mesenchymal Transition , Extracellular Matrix/physiology , Humans , Inflammation/enzymology , Inflammation/pathology , Matrix Metalloproteinase Inhibitors/pharmacology , Matrix Metalloproteinase Inhibitors/therapeutic use , Neoplasms/drug therapy , Neoplasms/pathology , Neoplastic Stem Cells/pathology , Tumor Microenvironment
4.
Biomed Res Int ; 2014: 548097, 2014.
Article in English | MEDLINE | ID: mdl-25309913

ABSTRACT

Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood worldwide and Mexico has reported one of the highest incidence rates. An infectious etiology has been suggested and supported by epidemiological evidences; however, the identity of the involved agent(s) is not known. We considered that early transmitted lymphotropic herpes viruses were good candidates, since transforming mechanisms have been described for them and some are already associated with human cancers. In this study we interrogated the direct role of EBV, HCMV, HHV6, and HHV7 human herpes viruses in childhood ALL. Viral genomes were screened in 70 bone marrow samples from ALL patients through standard and a more sensitive nested PCR. Positive samples were detected only by nested PCR indicating a low level of infection. Our result argues that viral genomes were not present in all leukemic cells, and, hence, infection most likely was not part of the initial genetic lesions leading to ALL. The high statistical power of the study suggested that these agents are not involved in the genesis of ALL in Mexican children. Additional analysis showed that detected infections or coinfections were not associated with prognosis.


Subject(s)
Bone Marrow/virology , Mass Screening , Precursor Cell Lymphoblastic Leukemia-Lymphoma/virology , Viruses/isolation & purification , Bone Marrow/pathology , Child , Cytomegalovirus/physiology , Demography , Female , Herpesvirus 4, Human/physiology , Herpesvirus 6, Human/physiology , Herpesvirus 7, Human/physiology , Humans , Limit of Detection , Male , Polymerase Chain Reaction , Prognosis
5.
Biomed Res Int ; 2013: 279505, 2013.
Article in English | MEDLINE | ID: mdl-23762835

ABSTRACT

Tumor-associated immune cells often lack immune effector activities, and instead they present protumoral functions. To understand how tumors promote this immunological switch, invasive and noninvasive breast cancer cell (BRC) lines were cocultured with a promonocytic cell line in a Matrigel-based 3D system. We hypothesized that if communication exists between tumor and immune cells, coculturing would result in augmented expression of genes associated with tumor malignancy. Upregulation of proteases MMP1 and MMP9 and inflammatory COX2 genes was found likely in response to soluble factors. Interestingly, changes were more apparent in promonocytes and correlated with the aggressiveness of the BRC line. Increased gene expression was confirmed by collagen degradation assays and immunocytochemistry of prostaglandin 2, a product of COX2 activity. Untransformed MCF-10A cells were then used as a sensor of soluble factors with transformation-like capabilities, finding that acini formed in the presence of supernatants of the highly aggressive BRC/promonocyte cocultures often exhibited total loss of the normal architecture. These data support that tumor cells can modify immune cell gene expression and tumor aggressiveness may importantly reside in this capacity. Modeling interactions in the tumor stroma will allow the identification of genes useful as cancer prognostic markers and therapy targets.


Subject(s)
Acinar Cells/pathology , Breast Neoplasms/pathology , Collagen/metabolism , Cyclooxygenase 2/metabolism , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 9/metabolism , Monocyte-Macrophage Precursor Cells/enzymology , Acinar Cells/metabolism , Breast Neoplasms/genetics , Cell Communication/genetics , Cell Line, Tumor , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Coculture Techniques , Dinoprostone/metabolism , Epithelial Cells/metabolism , Epithelial Cells/pathology , Extracellular Matrix/metabolism , Female , Gene Expression Regulation, Neoplastic , Humans , Models, Biological , Monocyte-Macrophage Precursor Cells/pathology , Neoplasm Invasiveness , Phenotype , Proteolysis , Solubility , Up-Regulation
6.
J Oncol ; 2013: 835956, 2013.
Article in English | MEDLINE | ID: mdl-23577028

ABSTRACT

Experimental and clinical studies indicate that cells of the innate and adaptive immune system have both anti- and pro-tumor activities. This dual role of the immune system has led to a conceptual shift in the role of the immune system's regulation of cancer, in which immune-tumor cell interactions are understood as a dynamic process that comprises at least five phases: immunosurveillance, immunoselection, immunoescape, oncotraining, and oncopromotion. The tumor microenvironment shifts immune cells to perform functions more in tune with the tumor needs (oncotraining); these functions are related to chronic inflammation and tissue remodeling activities. Among them are increased proliferation and survival, increased angiogenesis and vessel permeability, protease secretion, acquisition of migratory mesenchymal characteristics, and self-renewal properties that altogether promote tumor growth and metastasis (oncopromotion). Important populations in all these pro-tumor processes are M2 macrophages, N2 neutrophils, regulatory T cells, and myeloid derived suppressor cells; the main effectors molecules are CSF-1, IL-6, metalloproteases, VEGF, PGE-2, TGF- ß , and IL-10. Cancer prognosis correlates with densities and concentrations of protumoral populations and molecules, providing ideal targets for the intelligent design of directed preventive or anticancer therapies.

7.
Br J Cancer ; 101(5): 860-4, 2009 Sep 01.
Article in English | MEDLINE | ID: mdl-19707206

ABSTRACT

BACKGROUND: For a child to develop acute leukaemia (AL), environmental exposure may not be sufficient: interaction with a susceptibility factor to the disease, such as Down syndrome (DS), may also be necessary. We assessed whether breastfeeding and early infection were associated with the risk of developing AL in children with DS. METHODS: Children with DS in Mexico City, and either with or without AL, were the cases (N=57) and controls (N=218), respectively. Population was divided in children with AL and with acute lymphoblastic leukaemia (ALL) and also in children < or = 6 and >6 years old. RESULTS: Breastfeeding and early infections showed moderate (but not significant) association for AL, whereas hospitalisation by infection during the first year of life increased the risk: odds ratios (confidence interval 95%) were 0.84 (0.43-1.61), 1.70 (0.82-3.52); and 3.57 (1.59-8.05), respectively. A similar result was obtained when only ALL was analysed. CONCLUSION: We found that breastfeeding was a protective factor for developing AL and ALL, and during the first year of life, infections requiring hospitalisation were related to a risk for developing the disease in those children with DS >6 years of age. These data do not support the Greaves's hypothesis of early infection being protective for developing ALL.


Subject(s)
Breast Feeding/adverse effects , Down Syndrome/complications , Infections/complications , Infections/epidemiology , Leukemia, Myeloid/epidemiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology , Acute Disease , Adolescent , Case-Control Studies , Child , Child, Preschool , Down Syndrome/diagnosis , Down Syndrome/epidemiology , Female , Humans , Infant , Infant, Newborn , Leukemia, Myeloid/complications , Leukemia, Myeloid/diagnosis , Male , Odds Ratio , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Regression Analysis , Surveys and Questionnaires
8.
J Exp Med ; 194(11): 1583-96, 2001 Dec 03.
Article in English | MEDLINE | ID: mdl-11733573

ABSTRACT

Signal transduction through the B cell antigen receptor (BCR) is determined by a balance of positive and negative regulators. This balance is shifted by aggregation that results from binding to extracellular ligand. Aggregation of the BCR is necessary for eliciting negative selection or activation by BCR-expressing B cells. However, ligand-independent signaling through intermediate and mature forms of the BCR has been postulated to regulate B cell development and peripheral homeostasis. To address the importance of ligand-independent BCR signaling functions and their regulation during B cell development, we have designed a model that allows us to isolate the basal signaling functions of immunoglobulin (Ig)alpha/Igbeta-containing BCR complexes from those that are dependent upon ligand-mediated aggregation. In vivo, we find that basal signaling is sufficient to facilitate pro-B --> pre-B cell transition and to generate immature/mature peripheral B cells. The ability to generate basal signals and to drive developmental progression were both dependent on plasma membrane association of Igalpha/Igbeta complexes and intact immunoregulatory tyrosine activation motifs (ITAM), thereby establishing a correlation between these processes. We believe that these studies are the first to directly demonstrate biologically relevant basal signaling through the BCR where the ability to interact with both conventional as well as nonconventional extracellular ligands is eliminated.


Subject(s)
Antigens, CD/immunology , B-Lymphocytes/cytology , Receptors, Antigen, B-Cell/immunology , Signal Transduction/immunology , Animals , Antigens, CD/genetics , B-Lymphocytes/immunology , CD79 Antigens , Cell Differentiation , Cell Membrane/immunology , HeLa Cells , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Humans , Ligands , Mice , Receptors, Antigen, B-Cell/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Tumor Cells, Cultured
9.
Springer Semin Immunopathol ; 23(4): 333-50, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11826613

ABSTRACT

The B cell antigen receptor (BCR) is a protein complex expressed on the surface of immature and mature B cells. After ligand-induced aggregation, this complex generates signals that lead to a variety of biological outcomes, including survival, proliferation and differentiation. During B cell development intermediate forms of the BCR are expressed on the surface. The composition of these pro- and preBCR complexes reflects the ordered assembly of the BCR complex and they exist to generate signals for positive selection at defined developmental checkpoints. Because these receptors lack the ability to bind conventional ligands, the pro- and preBCR have been postulated to signal via ligand-independent processes. This ligand-independent or constitutive signal may also play a role in the survival of peripheral mature B cells. Here we discuss the evidence for ligand-independent functions for the BCR and postulate how it may be regulated and linked to biological processes associated with B cell development and survival.


Subject(s)
B-Lymphocytes/immunology , Lymphocyte Activation/immunology , Receptors, Antigen, B-Cell/immunology , Amino Acid Motifs , Animals , Bone Marrow/immunology , Cell Differentiation , DNA Nucleotidyltransferases/physiology , Gene Expression Regulation, Developmental , Gene Rearrangement, B-Lymphocyte , Genes, Immunoglobulin , Humans , Ligands , MAP Kinase Signaling System/physiology , Macromolecular Substances , Mammals/immunology , Mice , Models, Immunological , Receptors, Antigen, B-Cell/chemistry , Signal Transduction/immunology , Spleen/immunology , VDJ Recombinases , src-Family Kinases/physiology
10.
J Virol ; 74(17): 8166-75, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10933728

ABSTRACT

EBNA2 is an Epstein-Barr virus (EBV)-encoded protein that regulates the expression of viral and cellular genes required for EBV-driven B-cell immortalization. Elucidating the mechanisms by which EBNA2 regulates viral and cellular gene expression is necessary to understand EBV-induced B-cell immortalization and viral latency in humans. EBNA2 targets to the latency C promoter (Cp) through an interaction with the cellular DNA binding protein CBF1 (RBPJk). The EBNA2 enhancer in Cp also binds another cellular factor, C promoter binding factor 2 (CBF2), whose protein product(s) has not yet been identified. Within the EBNA2 enhancer in Cp, we have previously identified the DNA sequence required for CBF2 binding and also determined that this element is required for efficient activation of Cp by EBNA2. In this study, the CBF2 activity was biochemically purified and microsequenced. The peptides sequenced were identical to the hnRNP protein AUF1. Antibodies against AUF1 but not antibodies to related hnRNP proteins reacted with CBF2 in gel mobility shift assays. In addition, stimulation of the cellular cyclic AMP (cAMP)/protein kinase A (PKA) signal transduction pathway results in an increase in detectable CBF2/AUF1 binding activity extracted from stimulated cells. Furthermore, the CBF2 binding site was able to confer EBNA2 responsiveness to a heterologous promoter when transfected cells were treated with compounds that activate PKA or by cotransfection of plasmids expressing a constitutively active catalytic subunit of PKA. EBNA2-mediated stimulation of the latency Cp is also increased in similar cotransfection assays. These results further support an important role for CBF2 in mediating EBNA2 transactivation; they identify the hnRNP protein AUF1 as a major component of CBF2 and are also the first evidence of a cis-acting sequence other than a CBF1 binding element that is able to confer responsiveness to EBNA2.


Subject(s)
Cyclic AMP-Dependent Protein Kinases/physiology , Cyclic AMP/physiology , DNA-Binding Proteins/metabolism , Epstein-Barr Virus Nuclear Antigens , Herpesvirus 4, Human/genetics , Heterogeneous-Nuclear Ribonucleoprotein D , Nuclear Proteins , Promoter Regions, Genetic , RNA-Binding Proteins/metabolism , Signal Transduction , Amino Acid Sequence , Binding Sites , Cell Line , Cyclic AMP/metabolism , Cyclic AMP-Dependent Protein Kinases/metabolism , DNA/metabolism , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/isolation & purification , Gene Expression Regulation, Viral , Herpesvirus 4, Human/metabolism , Heterogeneous Nuclear Ribonucleoprotein D0 , Humans , Immunoblotting , Immunoglobulin J Recombination Signal Sequence-Binding Protein , Molecular Sequence Data , RNA-Binding Proteins/chemistry , RNA-Binding Proteins/isolation & purification , Repressor Proteins/metabolism , Sequence Analysis, Protein , Transcriptional Activation , Viral Proteins/metabolism
11.
J Virol ; 74(1): 379-89, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10590127

ABSTRACT

The Epstein-Barr virus (EBV) EBNA-LP and EBNA2 proteins are the first to be synthesized during establishment of latent infection in B lymphocytes. EBNA2 is a key transcriptional regulator of both viral and cellular gene expression and is essential for EBV-induced immortalization of B lymphocytes. EBNA-LP is also important for EBV-induced immortalization of B lymphocytes, but far less is known about the functional domains and cellular cofactors that mediate EBNA-LP function. While recent studies suggest that serine phosphorylation of EBNA-LP and coactivation of EBNA2-mediated transactivation are important, more detailed mutational and genetic studies are complicated by the repeat regions that comprise the majority of the EBNA-LP sequence. Therefore, we have used a comparative approach by studying the EBNA-LP homologues from baboon and rhesus macaque lymphocryptoviruses (LCVs) (baboon LCV and rhesus LCV). The predicted baboon and rhesus LCV EBNA-LP amino acid sequences are 61 and 64% identical to the EBV EBNA-LP W1 and W2 exons and 51% identical to the EBV EBNA-LP Y1 and Y2 exons. Five evolutionarily conserved regions can be defined, and four of eight potential serine residues are conserved among all three EBNA-LPs. The major internal repeat sequence also revealed a highly conserved Wp EBNA promoter with strong conservation of upstream activating sequences important for Wp transcriptional regulation. To test whether transcriptional coactivating properties were common to the rhesus LCV EBNA-LP, a rhesus LCV EBNA2 homologue was cloned and expressed. The rhesus LCV EBNA2 transcriptionally transactivates EBNA2-responsive promoters through a CBF1-dependent mechanism. The rhesus LCV EBNA-LP was able to further enhance rhesus LCV or EBV EBNA2 transactivation 5- to 12-fold. Thus, there is strong structural and functional conservation among the simian EBNA-LP homologues. Identification of evolutionarily conserved serine residues and regions in EBNA-LP homologues provides important clues for identifying the cellular cofactors and molecular mechanisms mediating these conserved viral functions.


Subject(s)
Epstein-Barr Virus Nuclear Antigens , Lymphocryptovirus/genetics , Viral Proteins/genetics , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , DNA, Complementary , Lymphocryptovirus/isolation & purification , Macaca mulatta/virology , Molecular Sequence Data , Papio/virology , Sequence Homology, Amino Acid , Sequence Homology, Nucleic Acid , Viral Proteins/chemistry , Viral Proteins/physiology
12.
J Virol ; 73(1): 826-33, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9847397

ABSTRACT

The Epstein-Barr virus (EBV) EBNA2 protein is a transcriptional activator that controls viral latent gene expression and is essential for EBV-driven B-cell immortalization. EBNA2 is expressed from the viral C promoter (Cp) and regulates its own expression by activating Cp through interaction with the cellular DNA binding protein CBF1. Through regulation of Cp and EBNA2 expression, EBV controls the pattern of latent protein expression and the type of latency established. To gain further insight into the important regulatory elements that modulate Cp usage, we isolated and sequenced the Cp regions corresponding to nucleotides 10251 to 11479 of the EBV genome (-1079 to +144 relative to the transcription initiation site) from the EBV-like lymphocryptoviruses found in baboons (herpesvirus papio; HVP) and Rhesus macaques (RhEBV). Sequence comparison of the approximately 1,230-bp Cp regions from these primate viruses revealed that EBV and HVP Cp sequences are 64% conserved, EBV and RhEBV Cp sequences are 66% conserved, and HVP and RhEBV Cp sequences are 65% conserved relative to each other. Approximately 50% of the residues are conserved among all three sequences, yet all three viruses have retained response elements for glucocorticoids, two positionally conserved CCAAT boxes, and positionally conserved TATA boxes. The putative EBNA2 100-bp enhancers within these promoters contain 54 conserved residues, and the binding sites for CBF1 and CBF2 are well conserved. Cp usage in the HVP- and RhEBV-transformed cell lines was detected by S1 nuclease protection analysis. Transient-transfection analysis showed that promoters of both HVP and RhEBV are responsive to EBNA2 and that they bind CBF1 and CBF2 in gel mobility shift assays. These results suggest that similar mechanisms for regulation of latent gene expression are conserved among the EBV-related lymphocryptoviruses found in nonhuman primates.


Subject(s)
Gene Expression Regulation, Viral , Herpesvirus 4, Human/genetics , Lymphocryptovirus/genetics , Promoter Regions, Genetic , Transcriptional Activation , Virus Latency/genetics , Animals , B-Lymphocytes/virology , Base Sequence , Conserved Sequence , DNA-Binding Proteins/metabolism , Enhancer Elements, Genetic , Epstein-Barr Virus Nuclear Antigens/physiology , Macaca mulatta , Molecular Sequence Data , Papio
13.
J Virol ; 72(1): 693-700, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9420275

ABSTRACT

The Epstein-Barr virus (EBV) EBNA2 protein is a transcriptional activator that regulates viral and cellular gene expression and is also essential for EBV-driven immortalization of B lymphocytes. The EBNA2-responsive enhancer in the viral latency C promoter (Cp) binds two cellular factors, CBF1 and CBF2. The precise role of the CBF2 protein for Cp enhancer function is presently unclear. CBF2 does not appear to interact with EBNA2 and binds just downstream of CBF1 between positions -339 and -368 in the Cp EBNA2 enhancer. Within this region an 8-bp sequence, CAGTGCGT, can be found, and a similar sequence is also located downstream of CBF1 binding sites in other EBNA2-responsive promoters. Previous studies have indicated that mutations and methylation in this sequence affect EBNA2 responsiveness. To investigate the requirements for CBF2 binding, we synthesized a series of oligonucleotides carrying double transversion mutations spanning both the conserved core sequence and outside flanking sequences. Surprisingly, mutations outside of the conserved core sequence in 4 bases immediately flanking the 5' end, GGTT, had the most deleterious effect on CBF2 binding. Mutations in the conserved core had a gradient effect, with those near the 5' end having the most deleterious effects on CBF2 binding. In addition, the affinities of CBF2 for binding to the LMP-1, LMP-2, and CD23 promoters were also measured. These promoters contain the conserved core but lack the 5' flanking GGTT motif and bound CBF2 weakly or not at all. Using Cp reporter plasmids containing CBF2 mutant binding sites, we were also able to show that at lower doses of EBNA2, Cp transactivation required a functional CBF2 binding site but that higher doses of EBNA2 transactivated CBF2 mutant promoters to 40% of wild-type levels. These assays indicate that CBF2 is important for EBNA2-mediated transactivation of the viral latency Cp. In addition, CBF2 activity was found to be associated with two polypeptides of 27 and 33 kDa.


Subject(s)
DNA-Binding Proteins/physiology , Epstein-Barr Virus Nuclear Antigens/genetics , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/physiology , Promoter Regions, Genetic , Trans-Activators/genetics , B-Lymphocytes/metabolism , B-Lymphocytes/virology , Base Sequence , Binding Sites/genetics , Cell Line , DNA Primers/genetics , DNA, Viral/genetics , DNA, Viral/metabolism , Herpesvirus 4, Human/pathogenicity , Humans , Molecular Sequence Data , Molecular Weight , Proteins/chemistry , Proteins/genetics , Proteins/physiology , Transcriptional Activation
14.
J Virol ; 69(4): 2629-32, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7884915

ABSTRACT

Most strains of animal rotaviruses are able to agglutinate erythrocytes, and the surface protein VP4 is the virus hemagglutinin. To map the hemagglutination domain on VP4 while preserving the conformation of the protein, we constructed full-length chimeras between the VP4 genes of hemagglutinating (YM) and nonhemagglutinating (KU) rotavirus strains. The parental and chimeric genes were expressed in insect cells, and the recombinant VP4 proteins were evaluated for their capacity to agglutinate human type O erythrocytes. Three chimeric genes, encoding amino acids 1 to 208 (QKU), 93 to 208 (QC), and 93 to 776 (QYM) of the YM VP4 protein in a KU VP4 background, were constructed. YM VP4 and chimeras QKU and QC were shown to specifically hemagglutinate, indicating that the region between amino acids 93 and 208 of YM VP4 is sufficient to determine the hemagglutination activity of the protein.


Subject(s)
Capsid Proteins , Capsid/genetics , Hemagglutination/genetics , Hemagglutinins, Viral/genetics , Rotavirus/genetics , Animals , Cells, Cultured , Cloning, Molecular , Humans , Nucleopolyhedroviruses/genetics , Recombinant Fusion Proteins/genetics , Spodoptera
SELECTION OF CITATIONS
SEARCH DETAIL